CS
ACUR

Credit Suisse’s Acura Pharmaceuticals ACUR Stock Holding History

Credit Suisse’s Portfolio ACUR Stock Details ACUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-2,436
Closed -$23K – 4781
2013
Q3 		$23K Sell
2,436
-9,976
-80% -$88.2K ﹤0.01% 4176
2013
Q2 		$117K Buy
+12,412
New +$140K ﹤0.01% 3987

Other funds holding ACUR

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.61B AUM 19.97% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Credit Suisse's ACUR Position: Q4 2013 in Review

Credit Suisse sold out of Acura Pharmaceuticals (ACUR) in Q4 2013, closing a stake of 2,436 shares — an estimated $23K sold.

Credit Suisse first reported a position in ACUR in Q2 2013 and held it in 2 quarters. The position peaked at $117K in Q2 2013. 33 funds tracked by Wall St. Rank hold ACUR as of Q4 2013.

  • Credit Suisse reported no remaining Acura Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Credit Suisse sold 2,436 Acura Pharmaceuticals shares in Q4 2013, an estimated $23K.
  • Credit Suisse first reported a position in Acura Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Credit Suisse's Acura Pharmaceuticals position peaked at $117K in Q2 2013.
  • 33 funds tracked by Wall St. Rank held Acura Pharmaceuticals as of Q4 2013.

Based on Credit Suisse's 13F filing for Q4 2013, filed 14 Feb 2014.